Reliability and Construct Validity of the NEI VFQ-25 in a Subset of Patients With Geographic Atrophy From the Phase 2 Mahalo Study.

[1]  S. Sivaprasad,et al.  Content validity of the NEI VFQ-25 in patients with geographic atrophy , 2017 .

[2]  B. Yaspan,et al.  Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration , 2017, Science Translational Medicine.

[3]  N. Bressler,et al.  Functional Reading Independence (FRI) Index: A New Patient-Reported Outcome Measure for Patients With Geographic Atrophy. , 2017, Investigative ophthalmology & visual science.

[4]  R. Klein,et al.  Age-Related Macular Degeneration and Quality of Life in Latinos: The Los Angeles Latino Eye Study. , 2016, JAMA ophthalmology.

[5]  R. Danis,et al.  Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects , 2015, Clinical ophthalmology.

[6]  D. Cook,et al.  Incidence of Late-Stage Age-Related Macular Degeneration in American Whites: Systematic Review and Meta-analysis. , 2015, American journal of ophthalmology.

[7]  Steffen Schmitz-Valckenberg,et al.  Geographic atrophy: clinical features and potential therapeutic approaches. , 2014, Ophthalmology.

[8]  E. Agrón,et al.  Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. , 2013, Ophthalmology.

[9]  Glenn J Jaffe,et al.  Semiautomated image processing method for identification and quantification of geographic atrophy in age-related macular degeneration. , 2011, Investigative ophthalmology & visual science.

[10]  N. Bressler,et al.  Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. , 2009, Investigative ophthalmology & visual science.

[11]  N. Bressler,et al.  Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. , 2009, Archives of ophthalmology.

[12]  V. Bonilha.  Age and disease-related structural changes in the retinal pigment epithelium , 2008, Clinical ophthalmology.

[13]  Neil M Bressler,et al.  Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. , 2007, Archives of ophthalmology.

[14]  G. Rubin,et al.  Reading With Central Scotomas: Is There a Binocular Gain? , 2006, Optometry and vision science : official publication of the American Academy of Optometry.

[15]  L. Smeeth,et al.  Is the NEI-VFQ-25 a useful tool in identifying visual impairment in an elderly population? , 2006, BMC ophthalmology.

[16]  Zachary Roth,et al.  Age-related macular degeneration: economic burden and value-based medicine analysis. , 2005, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[17]  MICHAEL D. CROSSLAND,et al.  Predicting Reading Fluency in Patients with Macular Disease , 2005, Optometry and vision science : official publication of the American Academy of Optometry.

[18]  E. Bass,et al.  Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: quality-of-life findings: SST report no. 12. , 2004, Ophthalmology.

[19]  E. Bass,et al.  Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization--SST Report No. 1. , 2003, Archives of ophthalmology.

[20]  R. Hays,et al.  Development of the 25-item National Eye Institute Visual Function Questionnaire. , 2001, Archives of ophthalmology.

[21]  K L Petre,et al.  Visual function and subjective quality of life compared in subjects with acquired macular disease. , 2000, Investigative ophthalmology & visual science.

[22]  G. Brown,et al.  Utility values and age-related macular degeneration. , 2000, Archives of ophthalmology.

[23]  J S Wolffsohn,et al.  The changing face of the visually impaired: the Kooyong low vision clinic's past, present, and future. , 1999, Optometry and vision science : official publication of the American Academy of Optometry.

[24]  D A Revicki,et al.  Recommendations for evaluating the validity of quality of life claims for labeling and promotion. , 1999, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[25]  Stuart I. Brown,et al.  The psychosocial impact of macular degeneration. , 1998, Archives of ophthalmology.

[26]  C Owsley,et al.  Identifying the content area for the 51-item National Eye Institute Visual Function Questionnaire: results from focus groups with visually impaired persons. , 1998, Archives of ophthalmology.

[27]  B S Hawkins,et al.  Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity. , 1997, Ophthalmology.

[28]  J. Evans.  Straightforward Statistics for the Behavioral Sciences , 1995 .

[29]  A. Damiano,et al.  The VF-14. An index of functional impairment in patients with cataract. , 1994, Archives of ophthalmology.

[30]  S. Whittaker,et al.  Visual Requirements for Reading , 1993, Optometry and vision science : official publication of the American Academy of Optometry.

[31]  R A Deyo,et al.  Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. , 1991, Controlled clinical trials.

[32]  GORDON E. LEGGE,et al.  Psychophysics of Reading. VIII. The Minnesota Low- Vision Reading Test , 1989, Optometry and vision science : official publication of the American Academy of Optometry.

[33]  M H Liang,et al.  Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research. , 1985, Arthritis and rheumatism.